Mineralys Therapeutics Inc. Company Profile
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics at a glance
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Radnor, PA. Mineralys Therapeutics is led by Dr. Jon Congleton and employs about 76 people. The company's shares have traded publicly since 2023.
At a market capitalization of $1.95 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001933414, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Mineralys Therapeutics do?
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Mineralys Therapeutics Inc.
- Ticker
- NASDAQ: MLYS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jon Congleton
- Employees
- 76
- Headquarters
- 150 N. Radnor Chester Road, Radnor, PA, United States
- Phone
- 888 378 6240
- Website
- mineralystx.com
- IPO year
- 2023
- Market cap
- $1.95B
- SEC CIK
- 0001933414
- Latest annual report
- 10-K · Mar 12, 2026
Companies similar to Mineralys Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LKFTLakefront Biotherapeutics ADR | 29.51 | -1.63% | $1.93B | vs MLYS |
| SDGRSchrodinger Inc. | 26.39 | -3.30% | $1.97B | vs MLYS |
| SRPTSarepta Therapeutics Inc. | 18.21 | +4.06% | $1.92B | vs MLYS |
| AGIOAgios Pharmaceuticals Inc. | 31.92 | +0.41% | $1.91B | vs MLYS |
| PRGOPerrigo Company plc | 14.50 | -0.34% | $2.01B | vs MLYS |
| PVLAPalvella Therapeutics Inc. | 131.34 | +0.57% | $1.89B | vs MLYS |
| ADRXADARx Pharmaceuticals Inc. | 17.68 | +1.99% | $1.89B | vs MLYS |
| TRVITrevi Therapeutics Inc. | 12.83 | -2.40% | $1.83B | vs MLYS |